4.5 Review

Physiological Signaling Specificity by Protein Tyrosine Phosphatases

Journal

PHYSIOLOGY
Volume 24, Issue 5, Pages 281-289

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physiol.00017.2009

Keywords

-

Categories

Funding

  1. National Institute of Health [AR-046524, DK-075776, DK-057751]
  2. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046524] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057751, R01DK075776] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protein tyrosine phosphatases (PTPs) are now recognized to be involved in a multitude of signaling events that control fundamental biological processes such as cell growth, differentiation, apoptosis, and cell movement. PTPs, which were initially thought to be less discriminating in their actions compared with their protein tyrosine kinase counterparts, are now known to regulate these various biological processes in a precise manner. This review will focus on the concept that PTPs exhibit remarkable signaling specificity through intrinsic differences between their PTP domains and through various modes of regulation that endows them with the capacity to promote unique physiological responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Genetics & Heredity

The sixth international RASopathies symposium: Precision medicine-From promise to practice

Karen W. Gripp, Lisa Schill, Lisa Schoyer, Beth Stronach, Anton M. Bennett, Susan Blaser, Amanda Brown, Rebecca Burdine, Emma Burkitt-Wright, Pau Castel, Sandra Darilek, Alwyn Dias, Tuesdi Dyer, Michelle Ellis, Gregg Erickson, Bruce D. Gelb, Tamar Green, Andrea Gross, Alan Ho, James Lloyd Holder, Shin-Ichi Inoue, Angie C. Jelin, Annie Kennedy, Richard Klein, Maria I. Kontaridis, Pilar Magoulas, Darryl B. McConnell, Frank McCormick, Benjamin G. Neel, Carlos E. Prada, Katherine A. Rauen, Amy Roberts, Pablo Rodriguez-Viciana, Neal Rosen, Gavin Rumbaugh, Anna Sablina, Maja Solman, Marco Tartaglia, Angelica Thomas, William C. Timmer, Kartik Venkatachalam, Karin S. Walsh, Pamela L. Wolters, Jae-Sung Yi, Martin Zenker, Nancy Ratner

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2020)

Article Medicine, Research & Experimental

Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines

Jae-Sung Yi, Sravan Perla, Liz Enyenihi, Anton M. Bennett

JCI INSIGHT (2020)

Article Biochemistry & Molecular Biology

An allosteric site on MKP5 reveals a strategy for small-molecule inhibition

Zachary T. K. Gannam, Kisuk Min, Shanelle R. Shillingford, Lei Zhang, James Herrington, Laura Abriola, Peter C. Gareiss, Georgios Pantouris, Argyrios Tzouvelekis, Naftali Kaminski, Xinbo Zhang, Jun Yu, Haya Jamali, Jonathan A. Ellman, Elias Lolis, Karen S. Anderson, Anton M. Bennett

SCIENCE SIGNALING (2020)

Article Cardiac & Cardiovascular Systems

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines

Jae-Sung Yi, Sravan Perla, Yan Huang, Kana Mizuno, Frank J. Giordano, Alexander A. Vinks, Anton M. Bennett

Summary: Low-dose dasatinib showed linear pharmacokinetic properties in NSML mice, with exposure-dependent inhibition of c-Src and PZR tyrosyl phosphorylation as well as AKT phosphorylation. A dose as low as 0.1 mg/kg of dasatinib prevented HCM in NSML mice and transcriptome analysis identified reversal of HCM-associated gene expression levels in the heart tissue.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

Review Cardiac & Cardiovascular Systems

An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies

Jae-Sung Yi, Sravan Perla, Anton M. Bennett

Summary: Mutations in the RAS/mitogen-activated protein kinase (MAPK) pathway cause a group of developmental diseases known as RASopathies. These diseases are characterized by a wide range of congenital heart defects, and targeted therapies for RASopathy-associated HCM have shown promise. However, safety and risk assessment in treating children remain crucial considerations.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

Article Immunology

MAP Kinase Phosphatase-5 Deficiency Protects Against Pressure Overload-Induced Cardiac Fibrosis

Chao Zhong, Kisuk Min, Zhiqiang Zhao, Cheng Zhang, Erhe Gao, Yan Huang, Xinbo Zhang, Margaret Baldini, Rajika Roy, Xiaofeng Yang, Walter J. Koch, Anton M. Bennett, Jun Yu

Summary: Cardiac fibrosis, a pathological condition associated with excessive ECM deposition in the myocardium, is regulated by processes not fully understood. Macrophage-specific MKP-5 was found to modulate pressure overload-induced cardiac fibrosis, with its deficiency resulting in upregulation of ECM-degrading MMP-9 expression in Ly6C(low) cardiac macrophages. This study indicates that MKP-5 may play a role in suppressing ECM-degrading activity through MAPK-mediated regulation of MMP-9 expression in cardiac macrophages.

FRONTIERS IN IMMUNOLOGY (2021)

Article Genetics & Heredity

The seventh international RASopathies symposium: Pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery

Maria Kontaridis, Amy E. Roberts, Lisa Schill, Lisa Schoyer, Beth Stronach, Gregor Andelfinger, Yoko Aoki, Marni E. Axelrad, Annette Bakker, Anton M. Bennett, Alberto Broniscer, Pau Castel, Caitlin A. Chang, Lukas Cyganek, Tirtha K. Das, Jeroen den Hertog, Emilia Galperin, Shruti Garg, Bruce D. Gelb, Kristiana Gordon, Tamar Green, Karen W. Gripp, Maxim Itkin, Maija Kiuru, Bruce R. Korf, Jeff R. Livingstone, Alejandro Lopez-Juarez, Pilar L. Magoulas, Sahar Mansour, Theresa Milner, Elisabeth Parker, Elizabeth Pierpont, Kevin Plouffe, Katherine A. Rauen, Suma P. Shankar, Shane B. Smith, David A. Stevenson, Marco Tartaglia, Richard Van, Morgan E. Wagner, Stephanie M. Ware, Martin Zenker

Summary: RASopathies are a group of genetic disorders caused by genes affecting the Ras/MAPK signaling pathway. Progress has been made in translating research findings to the clinic, with the use of pathway inhibitors for treatment. The seventh International RASopathies Symposium aimed to enhance new discoveries in the field and bring together stakeholders from various backgrounds.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

Review Pharmacology & Pharmacy

Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?

Shanelle R. Shillingford, Anton M. Bennett

Summary: Phosphatases and kinases play crucial roles in maintaining the balance between dephosphorylated and phosphorylated proteins for cellular functions. Imbalance or dysfunction in their activities can lead to unfavorable cellular effects and the development of diseases. Protein tyrosine phosphatases (PTPs) are attractive therapeutic targets due to their involvement in cell signaling and diseases, but they have been challenging in drug development. This article focuses on the progress in small-molecule inhibition of the mitogen-activated protein kinase (MAPK) phosphatases (MKPs), discussing successful strategies and inhibitor discovery tools, as well as the potential future of MKP inhibition.

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2023)

Article Chemistry, Medicinal

Defining the structure-activity relationship for a novel class of allosteric MKP5 inhibitors

Zira T. K. Gannam, Haya Jamali, Oh Sang Kweon, James Herrington, Shanelle R. Shillingford, Christina Papini, Erik Gentzel, Elias Lolis, Anton M. Bennett, Jonathan A. Ellman, Karen S. Anderson

Summary: This study explores the structure-activity relationship of a class of MKP5 inhibitors and designs and synthesizes a series of derivative compounds for evaluation of MKP5 inhibition. The crystal structures of enzyme-inhibitor complexes are further analyzed to elucidate the necessary requirements for MKP5 inhibition. The results lay the foundation for the development of more potent MKP5 allosteric inhibitors for the treatment of dystrophic muscle disease.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Editorial Material Biochemistry & Molecular Biology

Teaching an old dog new tricks: A new tool for protein tyrosine phosphatase substrate discovery

Anton M. Bennett

Summary: The identification of substrates for protein tyrosine phosphatases (PTPs) is crucial for understanding their function. In a recent study, Bonham et al. developed a modified method combining substrate-trapping mutations with proximity-labeling mass spectrometry (MS) to identify the protein substrates and interactors of PTP1B. This method revealed interaction networks in breast cancer cell models and discovered novel targets of PTP1B that regulate HER2 signaling pathways. This strategy represents a versatile new tool for identifying the functional interactions between PTPs and their substrates.

JOURNAL OF BIOLOGICAL CHEMISTRY (2023)

Article Medicine, General & Internal

SH2 Domain-Containing Phosphatase-SHP2 Attenuates Fibrotic Responses through Negative Regulation of Mitochondrial Metabolism in Lung Fibroblasts

Theodoros Karampitsakos, Apostolos Galaris, Ilianna Barbayianni, Giuseppe DeIuliis, Farida Ahangari, Fotis Sampsonas, Vasilina Sotiropoulou, Vassilis Aidinis, Anton M. Bennett, Jose D. Herazo-Maya, Nikolaos Xylourgidis, Petros Bakakos, Demosthenes Bouros, Naftali Kaminski, Argyrios Tzouvelekis

Summary: SHP2 downregulation may predispose fibroblasts to differentiate into myofibroblasts and play a role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Recent data have shown that SHP2 localizes to the mitochondrial intercristae, and its overexpression enhances mitochondrial metabolism leading to oxidative stress and senescence. Through a series of experiments, it was found that SHP2 attenuates fibrotic responses by negatively regulating mitochondrial metabolism and inducing autophagy.

DIAGNOSTICS (2023)

Meeting Abstract Biochemistry & Molecular Biology

MAP Kinase Phosphatases as Nodal Signal Regulators in Health and Disease

Anton Bennett

JOURNAL OF BIOLOGICAL CHEMISTRY (2023)

Meeting Abstract Hematology

Lack Of Map Kinase Phosphatase-5 In Macrophages Protects Ldlr-null Mice Against Atherogenesis

Xinbo Zhang, Zhiqiang Zhao, Margaret Baldini, Cheng Zhang, Bo Tao, Lei Zhang, Anton M. Bennett, Jun Yu

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2022)

Meeting Abstract Sport Sciences

The Role Of MAP Kinase Phosphatase-5 In Dystrophic Heart

Kisuk Min Min, Yan Huang, Anton Bennett

MEDICINE & SCIENCE IN SPORTS & EXERCISE (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

MKP-5 Deficiency Attenuates Pressure Overload-induced Cardiac Hypertrophy

Kisuk Min, Yan Huang, Frank J. Giordano, Sudip Bajpeyi, Anton M. Bennett

CIRCULATION (2020)

No Data Available